People usually search for this
Product Usage:
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY.
This designation allows the use of research chemicals strictly for in vitro testing and
laboratory experimentation only. All product information available on this website is for
educational purposes only. Bodily introduction of any kind into humans or animals is
strictly forbidden by law. This product should only be handled by licensed, qualified
professionals. This product is not a drug, food, or cosmetic and may not be misbranded,
misused or mislabeled as a drug, food or cosmetic.
Retatrutide 15mg
$300.00
Products will arrive in a lyophilized (powder) form for maximum stability
Retatrutide is a synthetic triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously — currently the most-studied next-generation incretin in clinical trials. The 15mg lyophilized vial extends research duration over 10mg formats and supports multi-week pharmacokinetic and dose-response protocols at ≥99% HPLC purity. Research use only.
Volume discounts
Auto-applied at checkout
Free shipping on orders of $200+
Compound Identity
COMPOUND NAME
Retatrutide
SYNONYMS
LY3437943, 2381089-83-2, EX-A7826E, GTPL13769
CAS NUMBER
2381089-83-2
MOLECULAR FORMULA
C221H342N46O68
MOLECULAR WEIGHT
~4992.6 Da
STRUCTURE
Synthetic 39-amino acid peptide
PEPTIDE SEQUENCE
Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{?-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
CHEMICAL STRUCTURE
Molecular Formula: C221H342N46O68
Molar Mass
4731 g/mol
Source: PubChem
Mechanism of Action
Retatrutide functions as a potent triple agonist at the GLP-1, GIP, and glucagon receptors. By simultaneously activating these receptors, it lowers blood glucose, enhances insulin secretion and sensitivity, reduces appetite, and increases energy expenditure, resulting in pronounced weight loss and improved metabolic health1,3.
1
GLP-1 Receptor (GLP-1R) Agonism
2
Stimulates glucose-dependent insulin secretion: Enhances pancreatic beta-cell insulin release, thus lowering blood glucose1,3,4.
3
Suppresses appetite (central action): Reduces hunger signals in the brain, leading to decreased food intake and weight loss1,2.
4
Slows gastric emptying: Contributes to satiety and reduces post-meal glucose spikes1,5.
5
Receptor binding affinity (EC50, Human) = 5.
79 nM
6
GIP Receptor (GIPR) Agonism
7
Further increases insulin secretion: Complementing the effects of GLP-1, GIPR activation improves pancreatic insulin response4.
8
May improve insulin sensitivity: Some studies show GIP agonism modulates lipid metabolism and energy homeostasis1,3.
9
Supports maintenance of lean mass during weight loss1.
10
Receptor binding affinity (EC50, Human) = 0.
0643 nM
11
Glucagon Receptor (GCGR) Agonism
12
Increases energy expenditure: Glucagon activation raises metabolic rate, which is thought to amplify fat loss.
This is distinct from the appetite-suppressing effect of GLP-1 and GIP.
13
Promotes breakdown of liver fat (hepatic steatosis): GCGR activity boosts fatty acid oxidation in the liver, explaining marked reductions in hepatic fat seen in trials1,2.
14
Enhances amino acid metabolism: Aids regulation of gluconeogenic and branched-chain amino acids, which are linked to metabolic health2.
15
Receptor binding affinity (EC50, Human) = 0.
775 nM
Biological Activity
Full agonist at human GLP-1, GIP, and glucagon receptors; shows robust anti-obesity, anti-diabetic, and cardiometabolic effects in preclinical and clinical studies, including significant reductions in body weight, glycemic markers, blood pressure, and lipids1,3,5.
Storage
- −20°C or below, protect from moisture and light
Drug Categories
Amino Acids, Peptides, and Proteins; Lipids
Additional Notes
- Administered via once-weekly subcutaneous injection in clinical trials.
- Engineered for DPP-IV resistance and long half-life via fatty acid conjugation1,3,5.
- Has demonstrated up to 24% weight reduction over 48 weeks and significant improvements in metabolic risk factors1,3.
- Currently under investigation for obesity, type 2 diabetes, and metabolic liver diseases.
Summary Table
Property
Description
CAS Number
2381089-83-2
Molecular Formula
C221H342N46O68
Molecular Weight (MW)
~4992.6 Da
Molar Mass
4731 g/mol
Mechanism of Action
Triple agonist at GLP-1, GIP, and glucagon receptors; lowers glucose, suppresses appetite, increases energy expenditure, and reduces weight
Biological Activity
Full agonist at target receptors; induces significant weight loss, glycemic control, and cardiometabolic benefits
Supplied Form
Lyophilized powder
Purity
≥ 98% (HPLC)
Storage
−20°C, protect from light and moisture
Drug Categories
Amino Acids, Peptides, and Proteins; Lipids
Additional Notes
Engineered for stability and extended half-life; advanced in clinical trials for obesity, diabetes, NAFLD
Disclaimer
For Research Use Only. Not intended for human or veterinary use. This compound is supplied solely for laboratory and R&D purposes.
Detailed Product Description
Retatrutide is a novel investigational medication classified as a triple hormone receptor agonist. Specifically, it acts as a single peptide that simultaneously activates three receptors involved in metabolic regulation: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). The compound consists of 39 amino acids and is structurally engineered for enhanced stability and once-weekly subcutaneous injection due to its extended half-life of approximately six days. Retatrutide is under clinical development as a treatment for obesity, type 2 diabetes, and related metabolic conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease).
Research Highlights
Induces Substantial Weight Loss: Clinical trials consistently demonstrate robust, dose-dependent reductions in body weight.
Up to 24.2% body weight reduction after 48 weeks has been observed with higher doses in people with obesity; these effects are greater than those reported for currently approved single or dual agonists1,3.
Improves Glycemic Control: In persons with type 2 diabetes, retatrutide lowers HbA1c and fasting glucose levels, with efficacy sometimes exceeding established glucose-lowering medications1,2.
Reduces Liver Fat: In individuals with MASLD, retatrutide leads to profound reductions (over 80% at high doses) in liver fat and often normalization of hepatic fat content—changes strongly linked to improved metabolic health1.
Improves Metabolic and Cardiovascular Biomarkers: Treatment results in lower blood pressure, improved insulin sensitivity, reduced triglycerides and non-HDL cholesterol, and favorable changes in adiponectin and leptin, all contributing to cardiovascular and metabolic benefits1,4.
Synergy of Triple Agonism
The simultaneous action on these three receptors achieves effects not observed with single- or dual-receptor agonists:
- Greater weight reduction, driven by combined appetite suppression (GLP-1, GIP) and increased energy expenditure (glucagon)1.
- Dramatic reduction of liver fat through synchronized effects on appetite, metabolism, and lipid oxidation1.
- Improved glucose regulation by boosting insulin secretion, reducing glucagon spikes, and enhancing insulin sensitivity1.
Pharmacokinetic Profile
Route of Administration
SC
Dosing Frequency
Once weekly
Half-Life
6 days
Formulation & Handling
- Reconstitute in sterile water or PBS (pH ~7.4) for in vivo/in vitro use
- Store at –20°C in aliquots to prevent freeze-thaw degradation
- Shelf-stable for 12 months under recommended storage condition
Clinical Trial Activity
Trial ID
Title
Phase
Study Type
Sponsor
NCT06297603
Retatrutide in T2D with Renal Impairment (TRANSCEND-T2D-3)
3
Interventional
Eli Lilly and Company
NCT06354660
Retatrutide in T2D with Diet & Exercise Alone (TRANSCEND-T2D-1)
3
Interventional
Eli Lilly and Company
NCT06383390
Retatrutide in Cardiovascular and Kidney outcomes in Adults with Obesity (TRIUMPH-Outcomes)
3
Interventional
Eli Lilly and Company
NCT06662383
A Study of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5)
3
Interventional
Eli Lilly and Company
NCT04881760
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
3
Interventional
Eli Lilly and Company
NCT04867785
Study of LY3437943 in Participants with Type 2 Diabetes
2
Interventional
Eli Lilly and Company
NCT04881760
Study of LY3437943 in Participants Who Have Obesity or Are Overweight
2
Interventional
Eli Lilly and Company
References
1
Sanyal, A. J. et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat. Med. 30, 2037–2048 (2024). https://doi.org/10.1038/s41591-024-03018-2
2
Coskun, T. et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 402, 529–544 (2023). https://doi.org/10.1016/S0140-6736(23)01053-X
3
Urva, S. et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes. Metab. 25, 2784–2788 (2023). https://doi.org/10.1111/dom.15167
4
Kaur, M. & Misra, S. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur. J. Clin. Pharmacol. 80, 669–676 (2024). https://doi.org/10.1007/s00228-024-03646-0
5
Jastreboff, A. M. et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N. Engl. J. Med. 389, 514–523 (2023). https://doi.org/10.1056/NEJMoa2301972
Quality & Purity
This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to ≥99% purity by HPLC with identity confirmed by mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Learn about our full quality and testing process →
Related Products
Bioregulators
Vesugen 20mg
$70.00
Read more 
Exercise
MOTS-C 40mg
$200.00
Add to cart 
GHRP
Tesamorelin 20mg
$200.00
Add to cart Related products
GHK-Cu 50mg
Summary Description: GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It has potent tissue remodeling, wound healing, antioxidant, and anti-inflammatory properties. GHK-Cu stimulates collagen and glycosaminoglycan synthesis, modulates inflammation, promotes angiogenesis, and supports tissue regeneration and repair. It has been widely studied for applications in dermatology, regenerative medicine, and aging-related research for its role in tissue rejuvenation and healing1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
GLP-1 10mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
MOTS-C 10mg
Summary Description: MOTS-c (Mitochondrial ORF of the 12S rRNA type c) is a mitochondrial-derived peptide that plays a vital role in regulating metabolism, energy balance, and cellular stress responses. Discovered in 2015, MOTS-c functions as a signaling molecule that helps the body respond to metabolic stress by improving glucose uptake, enhancing insulin sensitivity, and promoting fat metabolism. It acts as a mitochondrial messenger that communicates with the nucleus to maintain cellular homeostasis, making it a promising target for research on metabolic health, exercise performance, and healthy aging1-4.
Products will arrive in a lyophilized (powder) form for maximum stability
PT-141 10mg
Summary Description: PT-141 is a synthetic cyclic heptapeptide derivative of alpha-melanocyte stimulating hormone (?-MSH), designed to act as a potent and selective melanocortin receptor agonist, particularly at MC3 and MC4. It is primarily researched for its unique ability to induce sexual arousal and enhance sexual function in both men and women without acting via direct hormonal or vascular mechanisms. PT-141 is supplied strictly for laboratory research use1,2,4.
Products will arrive in a lyophilized (powder) form for maximum stability
TB-500 10mg
Summary Description: TB-500 is a synthetic heptapeptide analog of the actin-binding motif of thymosin ?4 (T?4), composed of the acetylated sequence Ac-LKKTETQ. This fragment conserves the principal bioactive domain associated with T?4’s regenerative activity. TB-500 has been shown to promote cell migration, angiogenesis, cytoskeletal reorganization, and anti-inflammatory signaling in preclinical models1,2. Due to its shorter sequence, TB-500 offers enhanced metabolic stability and amenability to synthetic optimization compared to the parent protein. While TB-500 is banned in competitive sports, it continues to be studied for its potential in promoting angiogenesis, tissue repair, and modulation of actin-binding proteins.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 20mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability
Testagen 20mg
Summary Description: Testagen is a synthetic, short peptide bioregulator that targets the regulation and restoration of testicular and endocrine system functions. Developed at the St. Petersburg Institute of Bioregulation and Gerontology, it has been shown in research models to stimulate protein synthesis in testicular cells, modulate gene expression linked to steroidogenesis, influence stem cell differentiation into functional Leydig-lineage cells, and counteract age-related involution of reproductive tissues. By binding to specific DNA sequences and protecting promoter regions from methylation, Testagen helps to maintain transcriptional activity in genes involved in hormone synthesis, with potential implications for sustaining optimal testosterone production under physiological stress or aging conditions1-3.
Products will arrive in a lyophilized (powder) form for maximum stability